Multiple Sclerosis Journal · 2006 · 132 citations · 26 references
PharmacyNeurologyPharmacotherapyNeuropharmacologyNeuropsychiatryPsychopharmacologyAntidepressant PharmacotherapyAntidepressant TherapyDepressionDepression PharmacotherapyDepressive DisordersMultiple SclerosisAntidepressant EfficacyAntidepressant MedicationsAntidepressant ResponseComorbid Depression ManagementDepression In Multiple SclerosisMajor Depressive Disorder DiagnosisPsychopharmacology In Multiple SclerosisThreshold Doses
UNLABELLED: The objective of this study was to examine the adequacy of antidepressant pharmacotherapy in a sample of patients with multiple sclerosis (MS) treated by neurologists. METHODS: MS patients under the care of neurologists were recruited from a large health maintenance organization. Major depressive disorder (MDD) was diagnosed using a structured telephone interview. Antidepressant treatment data were obtained from the HMO pharmacy database. RESULTS: Study participants included 260 patients with MS treated by 35 neurologists. A total of 67 (25.8%) patients met the criteria for MDD. Among the patients with MDD, 65.6% received no antidepressant medication, 4.7% received subthreshold doses from their neurologists, 26.6% received doses at threshold, and 3.1% received doses exceeding threshold. DISCUSSION: Depression was undertreated by the neurologists treating this sample of patients with comorbid MS and MDD. Potential solutions are discussed.
26
The Quality of Care for Depressive and Anxiety Disorders in the United States
Alexander S. Young, Ruth Klap, C D Sherbourne et al. · Archives of General Psychiatry · 2001 · 1.1K citations
Depression and multiple sclerosis
A. Dessa Sadovnick, Ronald A. Remick, J. B. Allen et al. · Neurology · 1996 · 532 citations
Medicine, Neurology, Psychiatry +17